Merck Stock Drops 2.94% Amid 48th Ranked Trading Volume as Keytruda Patent Concerns Loom

On April 1, 2025, Merck & Co., Inc. (MRK) experienced a decline of 2.94% in its stock price, with a trading volume of 12.18 billion, ranking 48th in the day's market activity.

Merck recently announced positive data from Phase 3 trials for its investigational, once-daily, oral, two-drug regimen of Doravirine/Islatravir (DOR/ISL). This development is significant as Merck continues to drive sales through its blockbuster drug, Keytruda, and new products.

Merck's executives are aware of the substantial revenue gap that will need to be filled once Keytruda goes off-patent. The company is focusing on developing new products to ensure sustained growth and mitigate the impact of losing patent protection for Keytruda.